INNOVATE: a phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian cancer-Updated safety and efficacy results
Sourced from:
Embase
Search for your institution's name below to login via Shibboleth
Previously accessed institutions
- (none)